177 related articles for article (PubMed ID: 18852126)
1. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts.
Sarup J; Jin P; Turin L; Bai X; Beryt M; Brdlik C; Higaki JN; Jorgensen B; Lau FW; Lindley P; Liu J; Ni I; Rozzelle J; Kumari R; Watson SA; Zhang J; Shepard HM
Mol Cancer Ther; 2008 Oct; 7(10):3223-36. PubMed ID: 18852126
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.
Gompels LL; Malik NM; Madden L; Jin P; Feldmann M; Shepard HM; Paleolog EM
Arthritis Res Ther; 2011; 13(5):R161. PubMed ID: 21982514
[TBL] [Abstract][Full Text] [Related]
7. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
[TBL] [Abstract][Full Text] [Related]
8. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
11. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
12. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
13. Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.
Gu J; Chen L; Shatos MA; Rios JD; Gulati A; Hodges RR; Dartt DA
Exp Eye Res; 2008 Feb; 86(2):322-34. PubMed ID: 18155194
[TBL] [Abstract][Full Text] [Related]
14. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.
Woisetschläger M; Antes B; Borrowdale R; Wiederkum S; Kainer M; Steinkellner H; Wozniak-Knopp G; Moulder K; Rüker F; Mudde GC
Biotechnol J; 2014 Jun; 9(6):844-51. PubMed ID: 24806546
[TBL] [Abstract][Full Text] [Related]
16. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes.
Munk M; Memon AA; Goetze JP; Nielsen LB; Nexo E; Sorensen BS
PLoS One; 2012; 7(7):e40243. PubMed ID: 22792252
[TBL] [Abstract][Full Text] [Related]
18. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
19. Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
Jin P; Zhang J; Beryt M; Turin L; Brdlik C; Feng Y; Bai X; Liu J; Jorgensen B; Shepard HM
Mol Med; 2009; 15(1-2):11-20. PubMed ID: 19048033
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
